SCHEMBL23715982

SCHEMBL23715982

CC(C)C(=O)Nc1cc(O)cc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 3/20 0.51
MDM4 O15151 2/20 0.50
TP53 P04637 2/20 0.50
CETP P11597 1/20 0.47
NQO2 P16083 1/20 0.44
LMNA P02545 1/20 0.44
HPRT1 P00492 1/20 0.44
GAA P10253 3/20 0.44
MDM2 Q00987 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KCNJ11 Q14654 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26885106 0.83 TRPV1 (0.50) MDM4TP53CETPLMNAGAA
SCHEMBL21973921 0.82 CDC25B (0.47) CDC25BNQO2HPRT1GAAL3MBTL1
SCHEMBL9464673 0.82 CDC25B (0.55) CDC25BNQO2LMNAGAAMAPT
SCHEMBL171696 0.80 KDM4E (0.62) MDM4TP53CETPLMNAGAA
SCHEMBL19847377 0.80 CDC25B (0.45) CDC25BNQO2HPRT1GAAMAPT
SCHEMBL26639942 0.78 CDC25B (0.51) CDC25BNQO2MAPTCYP1A2CYP2C19
SCHEMBL10040374 0.77 CDC25B (0.50) CDC25BNQO2GAAMAPTMEN1
SCHEMBL26886421 0.75 SLC40A1 (0.45) MDM4TP53CETPLMNAGAA
SCHEMBL19422040 0.74 NQO2 (0.55) CDC25BNQO2GAAMAPTCYP1A2
SCHEMBL26885018 0.74 RAB9A (0.51) MDM4TP53CETPLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339910-A1 RAS INHIBITORS AND METHODS OF USING THE SAME JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2023-10-26 US disclosed
US-20230339910-A1 RAS INHIBITORS AND METHODS OF USING THE SAME JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2023-10-26 US disclosed
WO-2021152149-A1 RAS INHIBITORS AND METHODS OF USING THE SAME JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339910-A1 RAS INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS CDC25B 564/4885MDM4 347/4885TP53 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.